$-0.12
(Market cap
$317 Mln
Recently Viewed
Clear AllMarket cap
$317 Mln
Revenue (TTM)
$503 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-6.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
8.5
Debt to Equity
-6.6
Book Value
$--
EPS
$-0.7
Face value
--
Shares outstanding
98,839,144
CFO
$-120.99 Mln
EBITDA
$-167.75 Mln
Net Profit
$-91.54 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Oncology Institute Inc (TOI)
| -12.9 | 11.5 | -23.8 | 113.8 | 65.0 | -21.1 | -- |
|
BSE Sensex*
| -9.5 | -2.9 | -9.0 | 3.2 | 8.6 | 9.0 | 12.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Oncology Institute Inc (TOI)
| 1,052.1 | -84.6 | 23.6 | -83.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Oncology Institute Inc (TOI)
|
3.1 | 317.3 | 502.7 | -60.6 | -7.2 | 999.2 | -- | 0.8 |
| 14.1 | 3,317.6 | 3,125.0 | -262.7 | 0.9 | -313.2 | -- | 20.5 | |
| 395.3 | 5,369.9 | 2,530.0 | 265.2 | 14.2 | 25.3 | 20.8 | 5.3 | |
| 53.6 | 2,770.7 | 941.5 | 105.7 | 14.5 | 29.4 | 26.5 | 7.4 | |
| 106.8 | 10,579.8 | 5,935.2 | 566.2 | 18.1 | 25.1 | 18.9 | 4.0 | |
| 19.4 | 4,634.0 | 2,347.6 | 128.4 | 4.5 | 25.2 | 39.9 | 8.1 | |
| 29.2 | 4,360.4 | 5,649.5 | 207.6 | 7.0 | 15.2 | 21.6 | 3.2 | |
| 55.9 | 4,252.4 | 2,040.2 | -18.7 | 5.0 | -1.9 | -- | 3.9 | |
| 15.2 | 4,254.5 | 1,163.6 | 78.0 | 26.1 | 15.4 | 55.4 | 7.0 | |
| 204.8 | 11,505.2 | 5,057.8 | 344.0 | 9.2 | 16.9 | 33.9 | 5.1 |
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services,... in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. Address: 18000 Studebaker Road, Cerritos, CA, United States, 90703 Read more
Executive Chairman of the Board
Mr. Richard Alan Barasch
Executive Chairman of the Board
Mr. Richard Alan Barasch
Headquarters
Cerritos, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Oncology Institute Inc (TOI) is $3.10 (NASDAQ) as of 08-Apr-2026 16:18 EDT. Oncology Institute Inc (TOI) has given a return of 65.02% in the last 3 years.
Since, TTM earnings of Oncology Institute Inc (TOI) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.40
|
-20.83
|
|
2024
|
-0.36
|
6.46
|
|
2023
|
-1.82
|
2.65
|
|
2022
|
879.28
|
1.09
|
|
2021
|
-58.89
|
6.18
|
The 52-week high and low of Oncology Institute Inc (TOI) are Rs 4.88 and Rs 1.29 as of 09-Apr-2026.
Oncology Institute Inc (TOI) has a market capitalisation of $ 317 Mln as on 07-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Oncology Institute Inc (TOI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.